BBT Biotech

BBT Biotech is a private, revenue-generating German CDMO and product company focused on biologics. It leverages integrated capabilities in upstream fermentation and downstream purification to manufacture a portfolio of APIs, including thrombolytic enzymes (streptokinase, urokinase) and probiotic/postbiotic strains. The company's value proposition is built on GMP-compliant manufacturing, in-house R&D and quality control, and serving clients from development through to commercial-scale production. Its established product sales and contract services position it in the growing market for biologics and live biotherapeutic products.

Integrated upstream (fermentation) and downstream (protein purification, ultrafiltration, lyophilization) process development and GMP manufacturing platform for microorganisms and proteins.

BBT competes with large, global CDMOs (e.g., Lonza, Catalent) and specialized microbial fermentation players. Its differentiation lies in its specific focus on viable bacteria and thrombolytic enzymes, integrated services from development to commercial API, and its mid-size, flexible operations based in a strong regulatory jurisdiction (Germany).